Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04703543
Evaluating the Role of Both PSMA and 64Cu-PET/CT Total Body in Patients With Locally Relapsed Prostate Cancer
Overview
The purpose of this study is to assess the detection rate of local relapse after radical prostatectomy with either PSMA or 64Cu-PET/CTs and whether the delineation of relapsed lesions using both methods can facilitate/change the therapeutic strategy of the radiation oncologist
Eligibility
Inclusion
- Local relapse at mpMR
- Performance Status 0-1 according to ECOG
- Localized prostate adenocarcinoma (M0), any PSA value, any Gleason Score
- Biochemical recurrence (two consecutive PSA values of at least 0.2 ng/ml)
- Previous radical surgery with subsequent undetectable PSA (\<0.2 ng/ml)
- M0 to 18F-choline PET/TC
- Informed written consent
Exclusion
- Presence of coxo-femoral implants
- Contraindication to MRI (metal prostheses, pacemakers, claustrophobia, etc.)
- Secondary bone lesions from prostate cancer or M1
- Previous pelvic radiotherapy
- Psychiatric diseases
- Detectable PSA after surgery
- Crohn's disease or ulcerative colitis (active phase)
- Hormone therapy started before staging examinations
Share your feedback
Help us improve your experience